# PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.

> **NCT02362620** · — · UNKNOWN · sponsor: **Centro Nacional de Investigaciones Oncologicas CARLOS III** · enrollment: 402 (estimated)

## Conditions studied

- Advanced Prostate Cancer
- Cabazitaxel
- Docetaxel

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02362620
- **Lead sponsor:** Centro Nacional de Investigaciones Oncologicas CARLOS III
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-05
- **Primary completion:** 2018-04
- **Final completion:** 2020-12
- **Target enrollment:** 402 (ESTIMATED)
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02362620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02362620, "PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02362620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*